Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 710 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... July 25, 2024 The Future Front Line: Pre-Med During COVID-19 September 8, 2020 FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer March 10, 2021 5 Ways Teens or Young Adults Can Cope With Loneliness During... July 11, 2023 Load more HOT NEWS How Pelvic Floor Therapy Can Help People With Prostate Cancer and... Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable... FDA Approves Ivosidenib for Myelodysplastic Syndromes New on NCI’s Websites for June 2022
